ArticleKidney international2018
Donor APOL1 high-risk genotypes are associated with increased risk and inferior prognosis of de novo collapsing glomerulopathy in renal allografts.
Article in Kidney international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 51 citations in OpenAlex.
- Genetic kidney disease in adults-the pathologists' perspective.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Review
- APOL1 Genotype and Patient Outcomes in US and South African Transplant Recipients With HIV who Received Kidneys From Donors With HIV.Transplantation · 2026Article
- Collapsing FSGS in a kidney transplant with a single APOL1 risk variant: a case report.BMC nephrology · 2026Article
- Article
- What's new in medical renal pathology 2025: Updates on podocytopathy and immunofluorescence staining in medical kidney.Journal of pathology and translational medicine · 2025Article
- Granulomatous Tubulointerstitial Nephritis as a Rare Cause of Allograft Failure: A Case Report.Cureus · 2024Article
- Post-transplant glomerular diseases: update on pathophysiology, risk factors and management strategies.Clinical kidney journal · 2024Review
- Collapsing Glomerulopathy.Advances in kidney disease and health · 2024Review
- Genetic versus self-reported African ancestry of the recipient and neighborhood predictors of kidney transplantation outcomes in 2 multiethnic urban cohorts.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2024Article
- Monogenic Kidney Diseases in Kidney Transplantation.Kidney international reports · 2024Review
- Collapsing glomerulopathy is likely a major contributing factor for worse allograft survival in patients receiving kidney transplants from black donors.Frontiers in medicine · 2024Article
- CMV-associated collapsing focal segmental glomerulosclerosis after kidney transplant in a pediatric patient.Pediatric transplantation · 2023Article
- Early recurrence of focal segmental glomerulosclerosis in a kidney transplant recipient withBMJ case reports · 2023Article
- The role of HLA antigens in recurrent primary focal segmental glomerulosclerosis.Frontiers in immunology · 2023Article
- Article
- Apoprotein L1 risk variants and kidney transplantation: a protocol for systematic review and meta-analysis.The Pan African medical journal · 2022Article
- Variant APOL1 protein in plasma associates with larger particles in humans and mouse models of kidney injury.PloS one · 2022Article
- Glomerular Diseases of the Kidney Allograft: Toward a Precision Medicine Approach.Seminars in nephrology · 2022Review
- Donor-Recipient Non-HLA Variants, Mismatches and Renal Allograft Outcomes: Evolving Paradigms.Frontiers in immunology · 2022Review
- Kidney allograft biopsy findings after COVID-19.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2021Article
Corrections and comments
- Commented on by
Authors and funding
19 authors at 3 institutions in 1 country.
Funding
Abstract
Collapsing focal segmental glomerulosclerosis (cFSGS) in the native kidney is associated with heavy proteinuria and accelerated renal failure. However, cFSGS in the renal allograft is less well characterized. Here we report clinico-pathologic features and APOL1 donor risk genotypes in 38 patients with de novo post-kidney transplant cFSGS. Recipients were 34% female and 26% African American. Concurrent viral infections and acute vaso-occlusion (including thrombotic microangiopathy, cortical necrosis, atheroembolization, and cardiac arrest with contralateral graft thrombosis) were present in 13% and 29% of recipients, respectively. Notably, 61% of patients had concurrent acute rejection and 47% received grafts from African American donors, of which 53% carried APOL1 high-risk genotypes. These frequencies of acute rejection and grafts from African American donors were significantly higher than in our general transplant population (35% and 16%, respectively). Patients had a median serum creatinine of 5.4 mg/dl, urine protein/creatinine 3.5 g/g, and 18% had nephrotic syndrome. Graft failure occurred in 63% of patients at an average of eighteen months post-index biopsy. By univariate analysis, donor APOL1 high-risk genotypes, post-transplant time, nephrotic syndrome, and chronic histologic changes were associated with inferior graft survival while acute vaso-occlusion was associated with superior graft survival. Donor APOL1 high-risk genotypes independently predicted poor outcome. Compared to native kidney cFSGS, post-transplant cFSGS had more acute vaso-occlusion but less proteinuria. Thus, de novo cFSGS is associated with variable proteinuria and poor prognosis with potential predisposing factors of African American donor, acute rejection, viral infection and acute vaso-occlusion. Additionally, donor APOL1 high-risk genotypes are associated with higher incidence and worse graft survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.